HOME >> MEDICINE >> NEWS
FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS

Phase III trials at one year demonstrate new level of efficacy 66% reduction in rate of relapses seen in AFFIRM monotherapy trial

Cambridge, MA; San Diego, CA; Dublin, Ireland November 23, 2004 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the U.S. Food and Drug Administration (FDA) has approved TYSABRI (natalizumab), formerly referred to as ANTEGREN, as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses. FDA granted Accelerated Approval for TYSABRI following Priority Review based on one-year data from two Phase III studies, the AFFIRM monotherapy trial and the SENTINEL add-on trial with AVONEX(Interferon beta-1a).

TYSABRI, the first humanized monoclonal antibody approved for the treatment of MS, inhibits adhesion molecules on the surface of immune cells. Research suggests TYSABRI works by preventing immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibers and their insulation.

"TYSABRI is a powerful and innovative therapy that offers new hope for hundreds of thousands of people living with MS," said James C. Mullen, chief executive officer, Biogen Idec. "We believe TYSABRI will revolutionize the treatment of MS and become the leading choice for patients and physicians."

"TYSABRI is a significant breakthrough for patients with MS," said Kelly Martin, president and chief executive officer, Elan. "The approval of TYSABRI, with its unique mechanism of action and new level of efficacy, has the potential to make a genuine difference in the lives of patients and families who struggle with the debilitating effects of this disease."

Results of the AFFIRM Monotherapy Trial

AFFIRM is a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients conducted in 99 sites worldwide, in which patients were
'"/>

Contact: Amy Losak
646-935-9317
Ketchum
23-Nov-2004


Page: 1 2 3 4 5 6

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. US FDA grants full approval to DOXIL(R) following submission of phase III data
4. Four teams awarded inaugural translational cancer research grants
5. Immigrants, beware: Living in the United States is fattening
6. Prevalence of obesity among immigrants increases with longer residency in US
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2020)... ... September 02, 2020 , ... RAM ... payers administering Medicare Advantage and Special Needs plans, is proud to support the ... Insurance Plans (AHIP). RAM is supporting the event as a sponsor and exhibitor ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... Surgeon with specialty fellowship training in aesthetic surgery of the face, breast, and ... – the only female-owned premier boutique plastic surgery and aesthetic practice in Southwest ...
(Date:8/31/2020)... ... 31, 2020 , ... Want to get moving, break up your routine, and ... is thrilled to launch its fourth annual STEPtember campaign in the United States to ... everyone wherever they are at this moment — encouraging people to move in the ...
(Date:8/31/2020)... , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & ... the planet are in a state of panic, experiencing deep anxiety, immense stress, and right ... a solution is timely when most people on the planet are experiencing a great degree ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & Young ... named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in its ... ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... , ... Hero Life Sciences announced today that it will be ... disposable face masks and N95 respirators in its manufacturing plant located in the City ... Americans are facing in trying to find quality disposable face masks during the COVID-19 ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... of Claude E. Hooton as President and Chief Executive Officer effective immediately. Dr. ... of the company’s Board of Managers. , Mr. Hooton, a seasoned business ...
(Date:8/26/2020)... ... August 25, 2020 , ... ProgenCell - Stem ... Treatment Center to give international and local patients a more comprehensive medical ... its leadership in the field of regenerative medicine and medical tourism. ProgenCell’s New ...
Breaking Medicine Technology:
Cached News: